Skip to content

High rate of resistance means azithromycin shouldn't be used to treat syphilis, warn doctors from San Francisco

Treatment interruption study stopped after excess number of AIDS events seen in people taking treatment breaks

Non-Hodgkin's lymphoma risk increased with prolonged high HIV viral load

Two integrase inhibitors now making progress in clinical trials

Gilead and BMS to seek regulatory approval for efavirenz, Truvada coformulation

Study finds antiretroviral therapy cost-effective in South African setting

Clinical and immunological benefits lasting at least three years reported by large Kenyan antiretroviral programme

ICAAC: Nevirapine’s manufacturer examines rates of liver toxicity in key study, finds once daily dose equally safe at lower CD4 count

ICAAC: Women who shed HSV in genitals shed more HIV